Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis

C. I. Santos, A. J. Huang, M. B. Abelson, C. S. Foster, M. Friedlaender, James P McCulley

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

A multicenter, randomized, double-masked, parallel-group study compared the long-term efficacy and safety of lodoxamide 0.1% ophthalmic solution and placebo in 118 patients with vernal keratoconjunctivitis. The test drugs were instilled four times daily for 90 days. Lodoxamide 0.1% ophthalmic solution was significantly (P < .05) more effective than placebo in lowering severity scores for epithelial disease and corneal staining, evidence of the superior efficacy of lodoxamide 0.1% ophthalmic solution in reversing the corneal complications commonly associated with moderate to severe vernal keratoconjunctivitis. Additionally, lodoxamide 0.1% ophthalmic solution ameliorated the other key signs of vernal keratoconjunctivitis, including upper tarsal papillae, limbal signs (papillae, hyperemia, and Trantas' dots), and conjunctival discharge. The between-group differences in the relief of symptoms (itching, tearing, and photophobia) were clinically significant but not always statistically significant. Treatment-related adverse events were reported with similar frequency in both treatment groups, and none were serious.

Original languageEnglish (US)
Pages (from-to)488-497
Number of pages10
JournalAmerican Journal of Ophthalmology
Volume117
Issue number4
StatePublished - 1994

Fingerprint

Allergic Conjunctivitis
Ophthalmic Solutions
Placebos
Corneal Diseases
Photophobia
Hyperemia
Pruritus
Staining and Labeling
Safety
lodoxamide ethyl
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. / Santos, C. I.; Huang, A. J.; Abelson, M. B.; Foster, C. S.; Friedlaender, M.; McCulley, James P.

In: American Journal of Ophthalmology, Vol. 117, No. 4, 1994, p. 488-497.

Research output: Contribution to journalArticle

Santos, C. I. ; Huang, A. J. ; Abelson, M. B. ; Foster, C. S. ; Friedlaender, M. ; McCulley, James P. / Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. In: American Journal of Ophthalmology. 1994 ; Vol. 117, No. 4. pp. 488-497.
@article{ba33bc3a0a1d49a29058fa6c5f4a63af,
title = "Efficacy of lodoxamide 0.1{\%} ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis",
abstract = "A multicenter, randomized, double-masked, parallel-group study compared the long-term efficacy and safety of lodoxamide 0.1{\%} ophthalmic solution and placebo in 118 patients with vernal keratoconjunctivitis. The test drugs were instilled four times daily for 90 days. Lodoxamide 0.1{\%} ophthalmic solution was significantly (P < .05) more effective than placebo in lowering severity scores for epithelial disease and corneal staining, evidence of the superior efficacy of lodoxamide 0.1{\%} ophthalmic solution in reversing the corneal complications commonly associated with moderate to severe vernal keratoconjunctivitis. Additionally, lodoxamide 0.1{\%} ophthalmic solution ameliorated the other key signs of vernal keratoconjunctivitis, including upper tarsal papillae, limbal signs (papillae, hyperemia, and Trantas' dots), and conjunctival discharge. The between-group differences in the relief of symptoms (itching, tearing, and photophobia) were clinically significant but not always statistically significant. Treatment-related adverse events were reported with similar frequency in both treatment groups, and none were serious.",
author = "Santos, {C. I.} and Huang, {A. J.} and Abelson, {M. B.} and Foster, {C. S.} and M. Friedlaender and McCulley, {James P}",
year = "1994",
language = "English (US)",
volume = "117",
pages = "488--497",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis

AU - Santos, C. I.

AU - Huang, A. J.

AU - Abelson, M. B.

AU - Foster, C. S.

AU - Friedlaender, M.

AU - McCulley, James P

PY - 1994

Y1 - 1994

N2 - A multicenter, randomized, double-masked, parallel-group study compared the long-term efficacy and safety of lodoxamide 0.1% ophthalmic solution and placebo in 118 patients with vernal keratoconjunctivitis. The test drugs were instilled four times daily for 90 days. Lodoxamide 0.1% ophthalmic solution was significantly (P < .05) more effective than placebo in lowering severity scores for epithelial disease and corneal staining, evidence of the superior efficacy of lodoxamide 0.1% ophthalmic solution in reversing the corneal complications commonly associated with moderate to severe vernal keratoconjunctivitis. Additionally, lodoxamide 0.1% ophthalmic solution ameliorated the other key signs of vernal keratoconjunctivitis, including upper tarsal papillae, limbal signs (papillae, hyperemia, and Trantas' dots), and conjunctival discharge. The between-group differences in the relief of symptoms (itching, tearing, and photophobia) were clinically significant but not always statistically significant. Treatment-related adverse events were reported with similar frequency in both treatment groups, and none were serious.

AB - A multicenter, randomized, double-masked, parallel-group study compared the long-term efficacy and safety of lodoxamide 0.1% ophthalmic solution and placebo in 118 patients with vernal keratoconjunctivitis. The test drugs were instilled four times daily for 90 days. Lodoxamide 0.1% ophthalmic solution was significantly (P < .05) more effective than placebo in lowering severity scores for epithelial disease and corneal staining, evidence of the superior efficacy of lodoxamide 0.1% ophthalmic solution in reversing the corneal complications commonly associated with moderate to severe vernal keratoconjunctivitis. Additionally, lodoxamide 0.1% ophthalmic solution ameliorated the other key signs of vernal keratoconjunctivitis, including upper tarsal papillae, limbal signs (papillae, hyperemia, and Trantas' dots), and conjunctival discharge. The between-group differences in the relief of symptoms (itching, tearing, and photophobia) were clinically significant but not always statistically significant. Treatment-related adverse events were reported with similar frequency in both treatment groups, and none were serious.

UR - http://www.scopus.com/inward/record.url?scp=0028347739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028347739&partnerID=8YFLogxK

M3 - Article

C2 - 8154531

AN - SCOPUS:0028347739

VL - 117

SP - 488

EP - 497

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -